A study printed in JAMA Network Open up emphasizes the discrepancy involving what it prices to produce copyright and the retail costs clients deal with. Despite the reduced manufacturing costs, Novo Nordisk has not publicly disclosed unique figures for copyright or its other product, Wegovy.